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BACKGROUND: The discovery of ERG/ETV1 gene rearrangements and PTEN gene loss warrants investigation in a mechanism-based
prognostic classification of prostate cancer (PCa). The study objective was to evaluate the potential clinical significance and natural
history of different disease categories by combining ERG/ETV1 gene rearrangements and PTEN gene loss status.
METHODS: We utilised fluorescence in situ hybridisation (FISH) assays to detect PTEN gene loss and ERG/ETV1 gene rearrangements in
308 conservatively managed PCa patients with survival outcome data.
RESULTS: ERG/ETV1 gene rearrangements alone and PTEN gene loss alone both failed to show a link to survival in multivariate analyses.
However, there was a strong interaction between ERG/ETV1 gene rearrangements and PTEN gene loss (Po0.001). The largest
subgroup of patients (54%), lacking both PTEN gene loss and ERG/ETV1 gene rearrangements comprised a ‘good prognosis’
population exhibiting favourable cancer-specific survival (85.5% alive at 11 years). The presence of PTEN gene loss in the absence
of ERG/ETV1 gene rearrangements identified a patient population (6%) with poorer cancer-specific survival that was highly signi-
ficant (HR¼ 4.87, Po0.001 in multivariate analysis, 13.7% survival at 11 years) when compared with the ‘good prognosis’ group.
ERG/ETV1 gene rearrangements and PTEN gene loss status should now prospectively be incorporated into a predictive model to
establish whether predictive performance is improved.
CONCLUSIONS: Our data suggest that FISH studies of PTEN gene loss and ERG/ETV1 gene rearrangements could be pursued for patient
stratification, selection and hypothesis-generating subgroup analyses in future PCa clinical trials and potentially in patient management.
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Prostate cancer (PCa) is the most commonly diagnosed male
cancer and the second commonest cause of male cancer related
mortality in the Western world (Ferlay et al, 2007). The clinical
behaviour and molecular pathology of PCa is highly variable.
There is an urgent need to dissect this inter-patient heterogeneity
with robust molecular biomarkers to accelerate the successful
conduct of clinical trials for this disease, optimise patient
treatment and minimise late drug development attrition (Betensky
et al, 2002; Attard et al, 2008a). Critically, identifying patient
subgroups that require less treatment from those that should be
targeted with more aggressive therapy is a key goal.
PTEN loss and ETS gene rearrangements are proposed to be
critically important and common molecular events in prostate
carcinogenesis (Trotman et al, 2003; Tomlins et al, 2005, 2008a;
Carver et al, 2009; King et al, 2009). In particular, recent
publications have addressed the relationship between the two
events in mouse models demonstrating cooperation (Carver et al,
2009; King et al, 2009). Deletion of all or part of the tumour
suppressor gene PTEN is a frequent event. Other classes of
alterations including mutations and post-translational modifica-
tions occur less frequently (Whang et al, 1998; Verhagen et al,
2006; Yoshimoto et al, 2007, 2008). Previous studies have
examined the prognostic significance of PTEN deletions by
fluorescence in situ hybridisation (FISH) with small patient
cohorts and biochemical recurrence as the outcome (Yoshimoto
et al, 2007, 2008). Similarly the clinical implications of the ETS
gene rearrangements (Tomlins et al, 2005, 2007) are not yet fully
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understood (Clark and Cooper, 2009), with their presence reported
as associated with both poor (Demichelis et al, 2007; Nam et al,
2007; Attard et al, 2008b) and good prognosis (Petrovics et al,
2005; Gopalan et al, 2009; Hermans et al, 2009). We reported
that deletion of the intermediate region between TMPRSS2 and
ERG combined with duplication of the TMPRSS2–ERG fusion
sequences is predictive of poor cancer-specific survival (Attard
et al, 2008b), an observation supported by other studies
(FitzGerald et al, 2008; Yoshimoto et al, 2008; Gopalan et al,
2009). The effect of PTEN loss on PCa survival and its relationship
to the ETS gene rearrangements is largely unknown.
To evaluate the natural history of the different disease variants
identified by PTEN, ERG and ETV1 FISH we evaluated a
retrospective cohort of conservatively managed men (Cuzick
et al, 2006). Immunohistochemistry (IHC) was not carried out
because of concerns regarding potential interobserver interpreta-
tion variability (Kirkegaard et al, 2006); lack of uniformity
regarding tissue processing as samples were taken from different
hospitals (Cuzick et al, 2006); and previous studies reporting
conflicting results with IHC (Bedolla et al, 2007; McCall et al, 2008;
Sircar et al, 2009). Rearrangements involving ETV4 and ETV5
have also been reported, but these are rare and therefore unlikely
to be used widely in a clinically applicable test (Kumar-Sinha et al,
2008).
PATIENTS AND METHODS
Patient cohort
Tissue microarrays (TMAs) were constructed from unselected
transurethral resection of prostate (TURP) specimens from
patients who received no initial treatment in a cohort of
conservatively managed men with PCa (Cuzick et al, 2006). Ethical
approval for the collection of the cohort was obtained from the
Ethics Review Committees at every collaborating hospital.
TMAs and FISH studies
Tissue microarrays were constructed as previously described
(Attard et al, 2008b). Areas of ‘cancer’ and ‘normal’ were identified
on the basis of histopathological examination of haematoxylin and
eosin and p63/AMACR-stained sections that flanked the TMA slice
used for FISH studies (Figure 1). To assess the frequency of PTEN
gene loss in TMA cancer cores, FISH procedures were carried out
as described previously for rearrangement at the ERG and ETV1
loci (Attard et al, 2008b, c). The same (or an immediately adjacent)
slice was stripped and rehybridised for PTEN. We selected PTEN
BACs that map to the minimum region of PTEN deletion in PCa as
previously described in xenografts and cell lines (Hermans et al,
2004). We used two, overlapping, DIG-labelled BAC probes to
the 50 end of the PTEN locus, RP11-765C10 and RP11-959L24,
and a commercially available CY-3 labelled DNA chromosome
10 centromere probe (chromosome 10 (p11.1Bq11.1 Abbott
Molecular, Des Plaines, IL, USA) (Figure 2A). Representative
images of nuclei with normal, heterozygous and homozygous
PTEN patterns are shown in Figures 1 and 2B.
Establishing PTEN cut-offs
Evaluation of the FISH results in each core containing cancer was
independently carried out by two operators (A-R and G-A) who
were unaware of clinical data. Signals were scored in at least 200
non-overlapping nuclei. We assumed that part of some nuclei can
be lost during slicing and therefore not all nuclei in a section
A B
C D
Figure 1 Haematoxylin and eosin (H & E), fluorescence in-situ hybridisation (FISH) and P63/alpha-methylacyl-CoA racemase (AMACR) on adjacent slides
(A) a prostate cancer gland with H & E staining; (B) ETV1 FISH in the same gland on an adjacent slide. Cartoon and magnified images of two nuclei are also
shown. The upper nucleus has four paired (ploidy) ETV1 probes and the lower nucleus has two paired ETV1 probes indicating wild-type ETV1; FISH for ERG
also showed paired probes indicating wild-type ERG (image not shown); (C) PTEN FISH in the same gland on an adjacent slide. Cartoon and magnified
images of one nucleus is shown. The nucleus has four (ploidy) chromosome, 10 centromeric probes (in red) and two PTEN probes (in green) indicating
heterozygous loss of PTEN; and (D) the same prostate cancer gland on an adjacent slide, which has absent P63 staining and AMACR positivity.
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would have their full probe complement. Using accepted
methodology described previously we estimated the degree of
technical artefact by studying nuclei in TMA cores with non-
malignant prostatic epithelium (Ventura et al, 2006). As cancer
nuclei may differ in size from non-malignant nuclei, we also
counted patterns of PTEN loss in cancer nuclei for which an overall
‘normal PTEN complement’ FISH score had been given. These
data are provided in Supplementary Figure 1 and Supplementary
Table 1.
Statistical analysis
Associations between PTEN status and categorical data were
examined using the w2 test for trend. Associations between
PTEN status and numerical variables were assessed using
analysis of variance. The primary endpoints for this study were
time to death from PCa and time to death from any cause.
Univariate and multivariate analyses were carried out by propor-
tional hazard (Cox) regression analysis (Cox and Oakes,
1984). The following variables, determined as described
previously (Cuzick et al, 2006), were included in the multivariate
analyses: centrally reviewed Gleason scores determined by
modern grading criteria, baseline PSA (PSA within 6 months of
diagnosis) and age at diagnosis. All P-values were two-sided and
all statistical analyses were carried out using Stata 10.0
(StataCorp, LP, College Station, TX, USA).
RESULTS
General
PTEN gene status was established from 678 cancer cores from 322
patients. Tissue cores can hybridise with variable efficiency for
different FISH probes. Moreover, cores can sometimes be lost in
the rehybridisation process. Therefore, ERG and ETV1 gene status
was available from 308 of the 322 patients with a PTEN score (662
TMA cancer cores). Demographics and characteristics for tumours
stratified for PTEN status alone are shown in Table 1 and
according to PTEN and ERG/ETV1 gene status shown in Table 2.
The median follow-up was 100 months (3–197 months).
A competing risk analysis demonstrated that after 11 years of
follow-up, 59% of men had died: 25% from PCa and 34% from
other causes; only 22% were alive without progression. Results are
described for both cause-specific prostate survival and overall
survival.
PTEN gene loss alone is not a significant predictor of
clinical outcome in multivariate analysis
There was no statistically significant difference in outcome
between the tumours with heterozygous and those with homozygous
Chr10 (q23.3)
C10orf59PTEN
Region of minimum PTEN deletion 
RP11-765C10
RP11-959L24
A
B
Normal Heterozygous Homozygous
Figure 2 Fluorescence in-situ hybridisation (FISH) detection of PTEN loss. (A) Position of two ‘PTEN’ BAC probes shown in green. The PTEN gene and
flanking gene C10orf59 are shown in dark blue. Arrows indicate the direction of transcription. (B) PTEN loss patterns. Green signals are probes that detect
PTEN and red signals are probes that detect the chromosome 10 centromere. Nuclei with normal PTEN complement are visualised in interphase as two
green and two red signals (left). Heterozygous PTEN loss results in the loss of one green signal (centre) and homozygous PTEN loss, the loss of two green
signals (right).
Table 1 Relationship of PTEN status with demographics and tumour
characteristics
PTEN status
Normal PTEN
(n¼ 266)
PTEN loss
(n¼ 56) P-valuea
Variable
Mean age±s.d. (years) 69±5 70±4 0.18
Classes of age (years)
p65 51 8 (14)
465–70 72 13 (15)
470–73 72 14 (16) 0.12
473–76 71 21 (23)
Gleason score
o7 146 5 (3)
¼ 7 65 18 (22) o0.001
47 55 33 (38)
Baseline PSA (ngml1)
p4 104 9 (8)
44–10 55 7 (11)
410–25 51 14 (21) o0.001
425–50 31 16 (34)
450–100 25 10 (29)
Clinical stageb
T1 81 6 (7)
T2 50 14 (22) o0.001
T3 19 19 (50)
Cancer in biopsyc
p6 74 2 (3)
46–20 75 5 (6)
420–40 38 10 (21) o0.001
440–75 31 13 (30)
475–100 45 26 (37)
aTest for trend in PTEN loss group (except for mean age). bRestricted to patients for
whom clinical stage is available. cRestricted to patients for whom extent of disease is
available.
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PTEN loss (data not shown). Therefore, the analyses presented
consider PTEN loss tumours as one group. Of the 322 patients with a
PTEN score, 266 (83%) had a normal PTEN score and 56 (17%) had
PTEN loss. There were significant associations between PTEN loss
and Gleason score (Po0.001), clinical stage (Po0.001), baseline
PSA (Po0.001) and cancer in biopsy (proportion of TURP chips
with disease or linear proportion of needle biopsy containing
disease) (Po0.001), but no association with age (Table 1). Univariate
Cox analysis demonstrated that compared to cancers with PTEN,
tumours with PTEN loss had significantly worse cause-specific
and overall survival (HR¼ 3.33, 95% CI¼ 2.11–5.26, Po0.001,
Figure 3A, and HR¼ 1.72, 95% CI¼ 1.24–2.38, P¼ 0.001). However,
in a multivariate model, PTEN loss did not retain significance as a
prognostic factor for PCa survival (HR¼ 1.19, 95% CI¼ 0.73–1.96,
P¼ 0.49) or overall survival (HR¼ 1.00, 95% CI¼ 0.70–1.44,
P¼ 0.99). Furthermore, even when Gleason score only was added
to the model, PTEN did not remain a significant independent
prognostic factor for PCa survival (HR¼ 1.61, 95% CI¼ 0.99–2.62,
P¼ 0.05) or overall survival (HR¼ 1.16, 95% CI¼ 0.82–1.65,
P¼ 0.41).
PTEN gene loss and ERG/ETV1 gene rearrangements
Univariate Cox analysis demonstrated that ERG/ETV1 gene
rearrangement status alone was a significant prognostic factor
for cause-specific and overall survival (HR¼ 2.17, 95%
CI¼ 1.39–3.40, P¼ 0.001 and HR¼ 1.58, 95% CI¼ 1.20–2.08,
P¼ 0.001). However, on multivariate Cox analysis ERG/ETV1 gene
rearrangement status alone was not a significant independent
prognostic factor for either cause-specific or overall survival
(HR¼ 0.93, 95% CI¼ 0.58–1.50, P¼ 0.78 and HR¼ 1.04, 95%
CI¼ 0.77–1.41, P¼ 0.80). We next considered PTEN and ERG/
ETV1 gene status together (Table 2). The 308 patients were
stratified into those that had an ERG or ETV1 gene rearrangement
in their cancers (122 patients, 40%) and those that did not
(186 patients, 60%). The patients were then further stratified as to
whether they had PTEN loss or not. There was a significant
association between PTEN score and ERG/ETV1 status (Po0.001)
with 66% of PTEN loss tumours also having an ERG/ETV1 gene
rearrangement compared with 34% of normal PTEN tumours
(Table 3). When the patients were stratified according to their
ERG/ETV1 gene status there was a significant interaction with
PTEN status (test for heterogeneity (Q (1df)¼ 20.7, Po0.001 and
Q (1df)¼ 20.9, Po0.001 in multivariate analysis for cause-specific
survival and overall survival, respectively). Cox analyses were
therefore conducted using the group with normal ERG/ETV1 and
normal PTEN as the reference.
PTEN gene loss with no ERG/ETV1 rearrangement
identifies a poor prognosis group
Univariate analysis demonstrated that patients with normal ERG/
ETV1 and PTEN loss had a significantly worse cause-specific and
overall survival (HR¼ 9.37, 95% CI¼ 4.68–18.76, Po0.001,
Figure 3B and HR¼ 3.14, 95% CI¼ 1.89–5.23, Po0.001 respec-
tively). In multivariate analysis cases with normal ERG/ETV1 and
Table 2 Relationship of PTEN and ERG/ETV1 status with demographics
and tumour characteristics
PTEN-ERG/ETV1 status
Normal
PTEN/
normal
ERG/ETV1
(n¼167)
Normal
PTEN/
rearranged
ERG/ETV1
(n¼ 85)
PTEN loss/
normal
ERG/ETV1
(n¼19)
PTEN loss/
rearranged
ERG/ETV1
(n¼ 37)
Variable
Mean age±s.d.
(years)
69±5 69±6 71±4 70±5
Classes of age (years)
p65 30 18 2 6
465–70 45 21 5 8
470–73 48 23 4 10
473–76 44 23 8 13
Gleason score
o7 107 29 4 1
¼ 7 37 27 4 14
47 23 29 11 22
Baseline PSA (ngml1)
p4 77 21 7 2
44–10 35 17 1 6
410–25 31 17 7 7
425–50 11 19 3 13
450–100 13 11 1 9
Clinical stagea
T1 58 18 2 4
T2 27 19 5 9
T3 9 8 4 15
Cancer in biopsy (%)b
p6 58 8 2 0
46–20 51 22 3 2
420–40 24 13 4 6
440–75 16 15 2 11
475–100 16 26 8 18
aRestricted to patients for whom clinical stage is available. bRestricted to patients for
whom extent of disease is available.
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Figure 3 (A) Prostate cancer survival according to PTEN gene status and
(B) according to PTEN and ERG/ETV1 gene status.
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PTEN loss had a significantly higher risk of dying from PCa
(HR¼ 4.87, 95% CI¼ 2.28–10.41, Po0.001). The cancer-specific
survival at 11 years was 13.7%. Similar results were found
for overall survival (HR¼ 2.40, 95% CI¼ 1.40–4.11, P¼ 0.001.
Gleason grades of these tumours (Table 2) demonstrate that in
21% of the normal ERG/ETV1 and PTEN loss tumours, Gleason
grade was o7 supporting a reclassification of this low Gleason
grade patient subgroup.
ERG/ETV1 gene rearranged tumours with and without
PTEN loss form two intermediate prognostic groups
In univariate analysis men with rearranged ERG/ETV1 and normal
PTEN exhibited significantly worse cause-specific and overall
survival (HR¼ 2.99, 95% CI¼ 1.70–5.25, Po0.001, Figure 3B and
HR¼ 1.80, 95% CI¼ 1.30–2.47, Po0.001 respectively) compared
with men with normal ERG/ETV1 and PTEN status. Similar results
were observed for cases with rearranged ERG/ETV1 and PTEN loss
(HR¼ 3.92, 95% CI¼ 2.06–7.48, Po0.001, Figure 3B and
HR¼ 1.77, 95% CI¼ 1.16–2.70, P¼ 0.008, respectively). In multi-
variate analysis, men with rearranged ERG/ETV1 and normal
PTEN had a marginally higher risk of dying from PCa (HR¼ 1.82,
95% CI¼ 1.01–3.26, P¼ 0.04), but no effect was observed in
cases with rearranged ERG/ETV1 and PTEN loss (HR¼ 0.98, 95%
CI¼ 0.49–1.97, P¼ 0.96). Similar results were found for overall
survival (HR¼ 1.37, 95% CI¼ 0.98–1.92, P¼ 0.06 and HR¼ 0.84,
95% CI¼ 0.52–1.35, P¼ 0.48, respectively). The cancer-specific
survival at 11 years for the rearranged ERG/ETV1 and normal
PTEN group was 59.8% and for the rearranged ERG/ETV1 and
PTEN loss group was 41.0% (Figure 3B).
No ERG/ETV1 gene rearrangement and no PTEN gene loss
identifies a good prognosis group
The largest group of patients (n¼ 167, 54%) comprised those who
had neither an ERG/ETV1 gene rearrangement nor PTEN loss.
This group (mean age 69±5 years) had a greater cause specific
survival (85.5% at 11 years) and overall survival when compared
with the three other groups (Figure 3B). In this good prognosis
group, 60 out of 167 (36%) had a Gleason grade X7. Prostate
cancer-specific deaths in this cohort were not confined to
the higher Gleason grades (Table 2). Of these 20 men who died
from PCa at 11 years, 5 (25%) had a Gleason score ofo7; 7 (35%)
had a Gleason score of 7; and the remaining 8 (40%) had a Gleason
score of 47.
DISCUSSION
We present the first large series in which PTEN and ERG/ETV1
gene status have been analysed together. We have identified
patient subgroups with high and low risk of death from PCa based
on PTEN and ERG/ETV1 status. There was no difference in
outcome between tumours with heterozygous and those with
homozygous PTEN loss and the PTEN loss tumours were therefore
considered as one group. This may be because in heterozygous
tumours by FISH, the other allele is lost by an alternative
mechanism (Whang et al, 1998; Verhagen et al, 2006). The ‘good
prognosis’ group (54%) lacked an ERG/ETV1 gene rearrangement
and PTEN gene loss (85.5% PCa survival at 11 years). The PCa-
specific deaths in this group did not only occur in the patients with
the higher Gleason grades, but across the Gleason grades. These
results highlight some inadequacy of Gleason grading in determin-
ing which patients require more intensive therapy for their PCa.
We also identified a patient group with a significant ‘poor
prognosis’. Patients lacking an ERG/ETV1 gene rearrangement but
with PTEN gene loss had the worst cause-specific survival of 13.7%
at 11 years. A proportion of patients in this group had a Gleason
score ofp7. These data are also potentially of clinical importance
as they identify a patient group who could be targeted to receive
more intensive neoadjuvant and adjuvant therapy when other
clinicopathological parameters recommended a more conservative
approach. This requires testing in prospectively designed studies.
Agents that specifically target the PI3K–AKT–mTOR pathway are
undergoing investigation in clinical trials (Yap et al, 2008) and
future studies should specifically evaluate these agents in this
subgroup.
One previous study (82 patients) reported that the absence of
PTEN loss and no ERG gene rearrangement is associated with
a longer time to biochemical recurrence and PTEN loss plus an
ERG gene rearrangement was associated with the shortest time to
biochemical recurrence (Yoshimoto et al, 2008). Our results are
similar in that those tumours that had neither an ERG gene
rearrangement nor PTEN loss were in a good prognostic group.
However, we did not show that the combination of the two
alterations was associated with poor outcome, and rather that
it is those tumours with PTEN loss but no ERG/ETV1 gene
Table 3 Summary results of multivariate Cox analyses for prostate cancer survival
Normal PTEN PTEN loss All
n¼ 167 n¼ 19
Normal ERG/ETV1 HR¼ ref HR¼ 4.87
95% CI¼ 2.28–10.41
Po0.001
HR¼ ref
GSo7: 64% GSo7: 21%
GS¼ 7: 22% GS¼ 7: 21%
ERG/ ETV-1 status n¼ 85 n¼ 37
Rearranged ERG/ETV1 HR¼ 1.82
95% CI¼ 1.01–3.26
P¼ 0.04
HR¼ 0.98
95% CI¼ 0.49–1.97
P¼ 0.96
HR¼ 0.93
95% CI¼ 0.58–1.50
P¼ 0.78
GSo7: 34% GSo7: 3%
GS¼ 7: 32% GS¼ 7: 38%
All (308 with ERG/ETV1 status) HR¼ ref HR¼ 1.12
95% CI¼ 0.68–1.86
P¼ 0.65
All (322) HR¼ ref HR¼ 1.19
95% CI¼ 0.73–1.96
P¼ 0.49
Abbreviations: CI¼ confidence interval; GS¼Gleason score; HR¼ hazard ratio.
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rearrangement that do particularly badly. These differences may be
a consequence of different study sizes or endpoints used.
ERG/ETV1 gene rearrangement positive and negative tumours
have been reported to have distinct chromosomal aberrations,
expression signatures and morphological features (Kumar-Sinha
et al, 2008), thus suggesting that they represent different PCa
classes. Our results support this hypothesis because PTEN loss was
only a significant independent prognostic factor for overall
survival, when analysed in the ERG/ETV1 gene non-rearranged
tumours. These results also raise the question of whether there are
other molecular abnormalities that are mutually exclusive of
ERG/ETV1 gene rearrangements that may contribute to the
worse outcome of patients with non-ERG/ETV1 gene rearranged/
PTEN loss tumours. In this respect, the recent observation that a
proportion of ETS-gene rearrangement negative cancers over-
express SPINK1 protein is of particular interest (Tomlins et al,
2008b). SPINK1 expression was linked to poorer outcome
(Tomlins et al, 2008b) and SPINK1 has been shown, when
overexpressed in colorectal and breast cancer cells, to function as
an autocrine growth factor that can stimulate the PI3K pathway
(Gouyer et al, 2008).
CONCLUSIONS
In conclusion, these data suggest that molecular characterisation of
PTEN, ERG and ETV1 gene status might be used in future to
determine the risk of PCa death. This has implications both for
potentially deciding which patients should be conservatively or
aggressively treated and also for stratification of patients in clinical
trials. At present clinical trial patients are stratified by clinico-
pathological features alone. Our results suggest that an imbalance
in numbers of patients with different PTEN and ERG/ETV1 gene
status in different study arms could falsely influence trial outcome
and needs to be accounted for.
ACKNOWLEDGEMENTS
This work was funded by the National Cancer Research Institute,
The Prostate Cancer Charity, The Grand Charity of Freemasons,
The Rosetrees Trust, The Bob Champion Cancer Trust and The
Royal Marsden Clinical Research Fund. Dr DM Berney is
supported by The Orchid Appeal. Dr JS de Bono was supported
by Cancer Research UK, the Medical Research Council, and
Prostate Cancer Research Foundation. Dr G Attard is a Prostate
Cancer Foundation Young Investigator and Drs Reid and Attard
have received Cancer Research UK funding.
Originality and Research Support: I declare that the content of the
manuscript is original and that it has not been published or
accepted for publication, either in whole or in part, in any form.
No part of the manuscript is currently under consideration for
publication elsewhere.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Attard G, Ang JE, Olmos D, de Bono JS (2008a) Dissecting prostate
carcinogenesis through ETS gene rearrangement studies: implications for
anticancer drug development. J Clin Pathol 61: 891–896
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D,
Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS,
Scardino P, Cuzick J, Cooper CS (2008b) Duplication of the fusion of
TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Oncogene 27: 253–263
Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A,
Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A,
De Bono JS, Scardino P, Cuzick J, Cooper CS (2008c) Heterogeneity and
clinical significance of ETV1 translocations in human prostate cancer.
Br J Cancer 99: 314–320
Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK,
Troyer DA, Ghosh PM (2007) Determining risk of biochemical
recurrence in prostate cancer by immunohistochemical detection of
PTEN expression and Akt activation. Clin Cancer Res 13: 3860–3867
Betensky RA, Louis DN, Cairncross JG (2002) Influence of unrecognized
molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:
2495–2499
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A,
Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP
(2009) Aberrant ERG expression cooperates with loss of PTEN to
promote cancer progression in the prostate. Nat Genet 41: 619–624
Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev
Urol 6: 429–439
Cox D, Oakes D (1984) Analysis of Survival Data. Chapman and Hall:
London, New York
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H,
Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome
among men with conservatively treated localised prostate cancer. Br J
Cancer 95: 1186–1194
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y,
Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW,
Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007)
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a
watchful waiting cohort. Oncogene 26: 4596–4599
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of
the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581–592
FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A,
Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL,
Huntsman DG (2008) Association of TMPRSS2-ERG gene fusion with
clinical characteristics and outcomes: results from a population-based
study of prostate cancer. BMC Cancer 8: 230
Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA,
Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE,
Gerald WL (2009) TMPRSS2-ERG gene fusion is not associated with
outcome in patients treated by prostatectomy. Cancer Res 69: 1400–1406
Gouyer V, Fontaine D, Dumont P, de Wever O, Fontayne-Devaud H,
Leteurtre E, Truant S, Delacour D, Drobecq H, Kerckaert JP, de Launoit Y,
Bracke M, Gespach C, Desseyn JL, Huet G (2008) Autocrine induction of
invasion and metastasis by tumor-associated trypsin inhibitor in human
colon cancer cells. Oncogene 27: 4024–4033
Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC,
Trapman J (2009) Overexpression of prostate-specific TMPRSS2(exon 0)-
ERG fusion transcripts corresponds with favorable prognosis of prostate
cancer. Clin Cancer Res 15: 6398–6403
Hermans KG, van Alewijk DC, Veltman JA, van Weerden W, van Kessel AG,
Trapman J (2004) Loss of a small region around the PTEN locus is a
major chromosome 10 alteration in prostate cancer xenografts and cell
lines. Genes Chromosomes Cancer 39: 171–184
King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH,
Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL
(2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway
activation in prostate oncogenesis. Nat Genet 41: 524–526
Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R,
Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in
immunohistochemical analysis of protein expression, time for a change?
Histopathology 48: 787–794
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene
fusions in prostate cancer. Nat Rev Cancer 8: 497–511
McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J (2008) Is PTEN
loss associated with clinical outcome measures in human prostate
cancer? Br J Cancer 99: 1296–1301
PTEN loss in prostate cancer
AHM Reid et al
683
British Journal of Cancer (2010) 102(4), 678 – 684& 2010 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A,
Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A (2007)
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence
after surgery for localised prostate cancer. Br J Cancer 97: 1690–1695
Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M,
Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA,
McLeod DG, Vahey M, Moul JW, Srivastava S (2005) Frequent over-
expression of ETS-related gene-1 (ERG1) in prostate cancer transcrip-
tome. Oncogene 24: 3847–3852
Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A,
Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA,
Squire JA (2009) PTEN genomic deletion is associated with p-Akt and
AR signalling in poorer outcome, hormone refractory prostate cancer.
J Pathol 218(4): 505–513
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS,
Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA,
Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM
(2007) Distinct classes of chromosomal rearrangements create oncogenic
ETS gene fusions in prostate cancer. Nature 448: 595–599
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q,
Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM (2008a)
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:
177–188
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW,
Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB,
Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
310: 644–648
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F,
Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K,
Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE,
Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H,
Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan
AM (2008b) The role of SPINK1 in ETS rearrangement-negative prostate
cancers. Cancer Cell 13: 519–528
Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A,
Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C,
Pandolfi PP (2003) Pten dose dictates cancer progression in the prostate.
PLoS Biol 1: E59
Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY,
Siebert R (2006) FISH analysis for the detection of lymphoma-associated
chromosomal abnormalities in routine paraffin-embedded tissue. J Mol
Diagn 8: 141–151
Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ,
Stoop H, van der Kwast TH, Trapman J (2006) The PTEN gene in locally
progressive prostate cancer is preferentially inactivated by bi-allelic gene
deletion. J Pathol 208: 699–707
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW,
Isaacs WB, Sawyers CL (1998) Inactivation of the tumor suppressor
PTEN/MMAC1 in advanced human prostate cancer through loss of
expression. Proc Natl Acad Sci USA 95: 5246–5250
Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P
(2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and
promises. Curr Opin Pharmacol 8: 393–412
Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA,
Squire JA (2007) FISH analysis of 107 prostate cancers shows that PTEN
genomic deletion is associated with poor clinical outcome. Br J Cancer
97(5): 678–685
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski
O, Zielenska M, Soares FA, Squire JA (2008) Absence of TMPRSS2:ERG
fusions and PTEN losses in prostate cancer is associated with a favorable
outcome. Mod Pathol 21: 1451–1460
PTEN loss in prostate cancer
AHM Reid et al
684
British Journal of Cancer (2010) 102(4), 678 – 684 & 2010 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
